Headlands Technologies LLC Boosts Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Headlands Technologies LLC increased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 94.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 26,736 shares of the biopharmaceutical company's stock after purchasing an additional 12,989 shares during the quarter. Headlands Technologies LLC's holdings in Agios Pharmaceuticals were worth $879,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. KBC Group NV increased its stake in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Agios Pharmaceuticals by 6.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company's stock worth $539,000 after purchasing an additional 688 shares in the last quarter. Alliancebernstein L.P. boosted its position in Agios Pharmaceuticals by 1.2% during the 4th quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock worth $2,021,000 after buying an additional 708 shares during the period. Atria Investments Inc increased its holdings in Agios Pharmaceuticals by 6.9% in the fourth quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock valued at $373,000 after purchasing an additional 737 shares during the period. Finally, Venturi Wealth Management LLC bought a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $33,000.

Remove Ads

Analysts Set New Price Targets

A number of analysts have commented on AGIO shares. Scotiabank upped their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, December 9th. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Royal Bank of Canada lifted their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a report on Tuesday, December 10th. StockNews.com lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. Finally, HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $56.57.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO traded down $0.53 on Monday, reaching $25.24. 306,222 shares of the company's stock were exchanged, compared to its average volume of 707,643. The stock has a fifty day simple moving average of $32.55 and a 200-day simple moving average of $40.19. Agios Pharmaceuticals, Inc. has a 52 week low of $24.41 and a 52 week high of $62.58. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of 2.20 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.